Why take organ damage in hypertension seriously?

Czech version

Authors: Eva Kociánová
Authors‘ workplace: I. interní klinika – kardiologická, Fakultní nemocnice Olomouc
Published in: Vnitř Lék 2022; 68(5): 303-308
Category: Review Articles
doi: https://doi.org/10.36290/vnl.2022.064

Overview

The focus of recent European guidelines has been early initiation of antihypertensive therapy in risk groups, rapid achievement of target blood pressure with fixed combinations of antihypertensive drugs, and the best possible management of an individual’s cardiovascular risk. Early intervention in the development of hypertension-mediated organ damage (HMOD) has been shown to have an effect on the subsequent reduction in the risk of cardiovascular events.

The point of HMOD origination correlates with the magnitude and duration of blood pressure elevation, and there is no clearly defined boundary from which vascular damage begins to develop. A reduction in blood pressure with pharmacotherapy demonstrably decreases the risk of ischaemic heart disease, stroke, as well as the mortality rate (1). Large clinical trials have consistently shown a significant reduction in the risk of these complications with antihypertensive medications across the entire spectrum from mild to severe hypertension, including hypertension in the elderly as well as isolated systolic hypertension (2). Based on the latest knowledge, a reduction in blood pressure by a mere 5 mm Hg has a cardioprotective effect even in normotensive individuals, which fundamentally changes the view on the diagnosis and definition of hypertension as a disease (3).

Keywords:

albuminuria – arterial hypertension – left ventricular hypertrophy – HMOD – organ damage

Sources

1. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta‑analysis. Lancet 2016; 387(10022):957-967.

2. Williams B, Mancia G, Spiering W et al. Desormais and E. S. C. S. D. Group „2018 ESC/ESH Guidelines for the management of arterial hypertension.“ Eur Heart J 2018; 39(33): 3021-3104.

3. Rahimi K, Bidel Z, Nazarzadeh M et al. Blood pressure treatment: how low should you go? – Authors’ reply. Lancet 2021; 398(10312):1684-1685.

4. Brown MJ, Williams B, Morant SV et al. British Hypertension Society’s and G. Treatment of Hypertension with Algorithm‑based Therapy Studies. „Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel‑group, double‑blind randomised phase 4 trial.“ Lancet Diabetes Endocrinol 2016; 4(2):136-147.

5. Cuspidi CR, Facchetti M, Bombelli M et al. High Normal Blood Pressure and Left Ventricular Hypertrophy Echocardiographic Findings From the PAMELA Population. Hypertension 2019; 73(3):612-619.

6. Wang C, Yuan Y, Zheng M et al. Association of Age of Onset of Hypertension With Cardiovascular Diseases and Mortality. J Am Coll Cardiol 2020; 75(23):2921-2930.

7. Leiba A, Fishman B, Twig G et al. Association of Adolescent Hypertension With Future End‑stage Renal Disease. JAMA Intern Med 2019; 179(4):517-523.

8. Perrone‑Filardi P, Coca A, Galderisi M et al. Non‑invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: A consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH). Eur Heart J Cardiovasc Imaging 2017; 18(9):945-960.

9. Sehestedt T, Jeppesen J. Hansen TW et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010; 31(7):883-891.

10. Ren Q, Ma C, Wang J et al. Albuminuria and other target organ damage in Chinese patients with hypertension and diabetes: A data analysis based on the ATTEND study. J Diabetes Complications 2020; 34(1): 107470.

11. Olsen MH, Wachtell K, Ibsen H. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006; 24(4):775-781.

12. Agarwal R. Ambulatory blood pressure and cardiovascular events in chronic kidney disease. Semin Nephrol 2007; 27(5):538-543.

13. Marwick TH, Gillebert TC, Aurigemma G et al. Recommendations on the Use of Echocardiography in Adult Hypertension: A Report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). J Am Soc Echocardiogr 2015; 28(7):727-754.

14. Pierdomenico SD, Lapenna D, Cuccurullo F. Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens 2008; 21(4):464-470.

15. Thomopoulos C, Parati G, Zanchetti A. Effects of blood‑pressure‑lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure: overview and meta‑analyses of randomized trials. J Hypertens 2017; 35(11):2138-2149.

16. Asmar RG, Pannier B, Santoni JP et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988; 78(4):941-950.

17. Okin PM, Wachtell K, Gerdts E. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.“J Hypertens 2014; 32(12):2472-2478; discussion 2478.

18. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117(25):e510-526.

19. Al‑Aly ZA, Zeringue J, Fu MI et al. Rate of kidney function decline associates with mortality. J Am Soc Nephrol 2010; 21(11):1961-1969.

20. Chronic Kidney Disease Prognosis, C. (2018). „Erratum: Evans M, Grams ME, Sang Y, et al., for the Chronic Kidney Disease Prognosis Consortium. Risk factors for prognosis in patients with severely decreased GFR. Kidney Int Rep. 2018;3:625-637.“ Kidney Int Rep 3(6): 1506.

21. Sehestedt T. Olsen MH. Subclinical organ damage and cardiovascular risk prediction. Blood Press 19(3):132-139.

22. Drawz PE, Alper AB, Anderson AH et al. Chronic Renal Insufficiency Cohort Study. Masked Hypertension and Elevated Nighttime Blood Pressure in CKD: Prevalence and Association with Target Organ Damage. Clin J Am Soc Nephrol 2016; 11(4):642-652.

23. Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45(2):198-202.

24. Schmieder RE, Mann JF, Schumacher H et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22(7):1353-1364.

25. Parving HH, Lewis JB, Ravid M et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006; 69(11):2057-2063.

26. Shi W, Wang H, Zhou Y et al. Synergistic interaction of hypertension and diabetes on chronic kidney disease: Insights from the National Health and Nutrition Examination Survey 1999-2006. J Diabetes Complications 2020; 34(2):107447.

27. Zhang W, Liu CY, Ji LN et al. Blood pressure and glucose control and the prevalence of albuminuria and left ventricular hypertrophy in patients with hypertension and diabetes. J Clin Hypertens (Greenwich) 2020; 22(2):212-220.

28. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004; 25(4):543-567.

29. Dawson A, Morris AD, Struthers AD. The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia 2005; 48(10):1971-1979.

30. Eguchi K, Boden‑Albala B, Jin Z. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol 2008; 101(12):1787-1791.

31. Rutter M., Parise H, Benjamin EJ et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex‑related differences in the Framingham Heart Study. Circulation 2003; 107(3):448-454.